Centro De Ingenieria Genetica Y Biotecnologia

Centro De Ingenieria Genetica Y Biotechnologia

Biorec S.a.

Centro De Ingenieria Genetica Y Biotecnologia Cigb

Biorec B.v.

Boris Ernesto Acevedo Castro

Osvaldo Reyes Acosta

Gerardo Enrique Guillen Nieto

Luis Javier González López

Silvio Ernesto Perea Rodriguez

Daniel Fernando Alonso

Lila Rosa Castellanos Serra

Daniel Eduardo Gomez

Jeovanis Gil Valdés

Lázaro Hiram Betancourt Núñez

Vladimir Besada Pérez

Jorge Fernández De Cossio Dorta Duque

Aniel Sánchez Puente

Yassel Ramos Gómez

Raimundo Ubieta Gómez

Maribel Guerra Vallespi

Jorge Victor Gavilondo Cowley

Ernesto Galban Rodriguez

Alexis Musachio Lasa

Ricardo De La Caridad Silva Rodriguez

Omar Lopez Ocejo

Alexis Musacchio Lasa

Gerardo Enrique Guillén Nieto

Hilda Elisa Garay Perez

Luis Enrique Fernández Molina

Yasser Perera Negrin

Arielis Rodríguez Ulloa

Hilda Elisa Garay Pérez

Isis Del Carmen Torrens Madrazo

Mónica Bequet Romero

Yuliet Mazola Reyes

Ania De La Nuez Veulens

Rolando Eduardo Rodriguez Fernandez

Roberto Vera Alvarez

Dania Marcia Vásquez Blomquist

Arielis Rodriguez Ulloa

Luis Tomás Sorell Gómez

Dania Marcia Vázquez Blomquist

Isis Del Carmen Torréns Madrazo

Milaid Granadillo Rodriguez

Silvio Ernesto Perea Rodríguez

Yasser Perera Negrín

Maribel Guerra Vallespí

Silvio Ernesto Perea RODRÍGUEZ

Raimundo Ubieta GÓMEZ

Hilda Elisa Garay PÉREZ

Luis Javier GONZÁLEZ LÓPEZ

Dania Marcia Vazquez Blomquist

Ricardo De Silva Rodriguez

Monica Bequet Romero

Vladimir Besada Perez

Jorge Fernandez De Cossio Dorta Duque

Lazaro Hiram Betancourt Nunez

Yassel Ramos Gomez

Isis Del Torrens Madrazo

Luis Enrique Fernandez Molina

Luis Javier Gonzalez Lopez

This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa, velcade (bortezomib), cytarabine (Ara C), fludarabine and mitroxantrone. The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs

This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.

Active antiangiogenic therapy

This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

Chemical compounds derived by in silico molecular modelling, having a well defined structure suitable for the blocking of the phosphorylation event, through the specific interaction of the chemical with the Casein Kinase 2 enzyme substrate phosphorylation domain or it's neighbourhood. This invention comprises also the pharmaceutical compositions containing such compounds, and their use in the preparation of medicines or agents for the treatment of diseases or conditions related with neoplasic processes.

Antineoplastic compounds and pharmaceutical compositions thereof

The present invention relates to use of a new cell penetrating peptides (CPP) and in particular to the region 32-51 of protein(LALF) and its analogous. This invention refers to compositions containing these peptides associated to biomolecules with therapeutics properties. This invention consist of compositions comprise the covalent fusion of biomolecules, between this human papillomavirus antigens (HPV) to these CPP for induce a potent immune cellular responses against HPV and HPV protein antigen-exhibiting cells including HPV-associated tumors. The referred compositions are applicable in the pharmaceutical industry as vaccine for therapeutic use in human.

Cell penetrating peptides and its use fused to biomolecules with therapeutic action

The present invention is related to the development of peptides derived from the sequence HYRIKPTFRRLKWKYKGKFW (SEQ ID NO.: 13), showing amino acid substitutions, these peptides unable to bind to the lipopolysaccharides and bearing anti-tumoral and immunomodulatory capacities. These peptides alone or in combination are useful to treat cancer, and also in synergy with conventional therapies.

Immunomodulatory and anti-tumour peptides

A non-instrumental assay for the diagnosis of celiac disease based on the general immunochromatographic assay principles. The assay is rapid and simple and allows the reliable detection of anti transglutaminase antibodies, of both IgA and IgG isotype, in samples of human serum, plasma or blood, using as tracer the antigen transglutaminase conjugated to a colored substance, like colloidal gold or colored latex particles. The conjugated antigen is deposited onto an inert fibrous support, from where it can be released by a liquid sample. The antibodies in the sample react with the conjugated antigen developing an immunocomplex that migrates through a carrier membrane, like nitrocellulose or nylon with a pore size that allows a laminar flow of the reagents, until it reacts with the same antigen transglutaminase immobilized onto a reactive zone of the membrane. As a consequence of this reaction the immunocomplex will be trapped in the reaction site and a colored signal will be seen. Therefore a visually detectable signal in the reactive zone of the membrane indicates a positive result for the detection of anti transglutaminase antibodies in the sample.

Assay for anti transglutaminase antibodies detection useful in celicac disease diagnosis

Growing community of inventors

Ciudad de la Habana, Cuba

Boris Ernesto Acevedo Castro